Global vaccine supply. The increasing role of manufacturers from middle income countries.
Donald P Francis, Yu-Ping Du, Alexander R Precioso
https://pubmed.ncbi.nlm.nih.gov/25110294/Actively Recruiting
Led by Butantan Institute · Updated on 2026-04-02
700
Participants Needed
5
Research Sites
8 weeks
Total Duration
Researchers are assessing the safety and immune response of two versions of a monovalent influenza vaccine candidate A H5N8 designed for adults and older adults. This vaccine, developed by the Instituto Butantan, aims to prepare for potential outbreaks of avian type AH5 influenza in humans. The study is a randomized, double-blind, placebo-controlled Phase III clinical trial focused on pandemic preparedness. Participants will receive one of two vaccine formulations, either containing 7.5 mcg or 15 mcg of hemagglutinin HA combined with the IB160 adjuvant, or a placebo of phosphate buffered saline. Each dose is 0.5 mL. The study will evaluate safety through the occurrence of local and systemic side effects within seven days after each vaccination and will assess the immune response 21 days following the second dose. During the trial, participants will be monitored for adverse events and reactions through diaries and clinical visits. Blood samples will be collected to measure seroprotection and seroconversion rates, indicating immune response. Safety assessments will continue for up to six months to record any serious or special interest adverse events. Participants are expected to comply with scheduled visits and procedures over the study period, which begins in September 2025 and ends in October 2027.
CONDITIONS
Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Butantan Institute
Lead Sponsor
Butantan Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 42 days (from first to second dose plus 21 days post second dose)
Participants receive two doses of the monovalent influenza vaccine A (H5N8) or placebo, with safety monitoring for adverse events within 7 days after each vaccination.
2 vaccination visits and weekly safety follow-up visits for 7 days after each vaccination
Duration - 6 months
Participants are monitored for safety, including adverse events of special interest and serious adverse events, for up to 6 months after the last vaccination.
Periodic visits during the 6-month follow-up
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Donald P Francis, Yu-Ping Du, Alexander R Precioso
https://pubmed.ncbi.nlm.nih.gov/25110294/Tazio Vanni, Beatriz C Thomé, Erin Sparrow...
https://pubmed.ncbi.nlm.nih.gov/36256646/Milena Apetito Akamatsu, Vitor Anselmo Sakihara, Bianca Pereira Carvalho...
https://pubmed.ncbi.nlm.nih.gov/32492039/Cosue Miyaki, Mauricio Meros, Alexander R Precioso...
https://pubmed.ncbi.nlm.nih.gov/21684420/Butantan Institute
Lead Sponsor
Butantan Foundation
Collaborating Sponsor